Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson purchased 34,000 shares of the business's stock in a transaction on Thursday, November 19th. The shares were acquired at an average price of $3.58 per share, with a total value of $121,720.00. Following the completion of the transaction, the director owned 112,405 shares of the company's stock, valued at approximately $402,409.90. This trade represents a 43.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Annexon Trading Down 9.2%
Shares of NASDAQ:ANNX traded down $0.32 on Friday, reaching $3.10. 4,454,126 shares of the company traded hands, compared to its average volume of 3,061,374. The stock has a market capitalization of $590.40 million, a P/E ratio of -2.98 and a beta of 1.43. The business's 50-day simple moving average is $3.94 and its 200 day simple moving average is $5.05. The company has a current ratio of 5.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.35. Annexon, Inc. has a 52 week low of $3.07 and a 52 week high of $7.18.
Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.03. As a group, equities analysts anticipate that Annexon, Inc. will post -1.03 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Annexon from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. JPMorgan Chase & Co. raised their target price on Annexon from $14.00 to $15.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Annexon in a report on Thursday, October 15th. Finally, Citizens Jmp upgraded Annexon from an "underperform" rating to a "market perform" rating in a research report on Thursday, August 13th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Annexon presently has an average rating of "Hold" and a consensus target price of $13.33.
Get Our Latest Stock Report on Annexon
Institutional Investors Weigh In On Annexon
Several institutional investors and hedge funds have recently modified their holdings of ANNX. Redmile Group LLC boosted its stake in shares of Annexon by 44.8% during the 1st quarter. Redmile Group LLC now owns 14,549,768 shares of the company's stock valued at $80,606,000 after purchasing an additional 4,499,124 shares in the last quarter. BlackRock Inc. bought a new position in Annexon in the second quarter worth about $77,312,000. Bank of America Corp DE lifted its holdings in Annexon by 165.3% in the first quarter. Bank of America Corp DE now owns 4,259,995 shares of the company's stock worth $23,600,000 after buying an additional 2,654,414 shares during the period. Siren L.L.C. purchased a new stake in Annexon in the first quarter worth about $21,931,000. Finally, Palo Alto Investors LP purchased a new stake in Annexon in the second quarter worth about $16,833,594.
Annexon Company Profile
(
Get Free Report)
Annexon is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.